ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023 Annual General Meeting held on June 29, 2023
June 30, 2023 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
Annual General Meeting 2023
June 08, 2023 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 8, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...
Tocolytic Agents Market to a Steady Revenue CAGR of 5.3% by 2031 | Growth Plus Reports
May 09, 2023 22:30 ET
|
Growth Plus Reports
Newark, New Castle, USA, May 09, 2023 (GLOBE NEWSWIRE) -- Growth Plus Reports estimated the size of the global market for tocolytic agents in 2022, and it is expected to increase at a revenue CAGR...
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer
May 02, 2023 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s...
ObsEva Annual Report 2022
April 28, 2023 12:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – April 28, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel...
ObsEva Announces Change of Central Securities Depositary
April 20, 2023 07:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 20, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing...
ObsEva Announces Change of Central Securities Depositary
April 20, 2023 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 20, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing...
Endometrial Cancer Market Growing Significantly | AstraZeneca, Karyopharm, Evergreen therapeutics, ImmunoGen, Inc., Merck, Tesaro, Inc., Abbott, Roche, Chimerix, Bayer, ImmunoGen, Inc., Incyte, Eli Lilly, Gilead, Genentech Expected to Boost
April 03, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 03, 2023 (GLOBE NEWSWIRE) -- Endometrial Cancer Market Growing Significantly | AstraZeneca, Karyopharm, Evergreen therapeutics, ImmunoGen, Inc., Merck, Tesaro, Inc., Abbott,...
ObsEva Files Year End 2022 Financial Statements
March 31, 2023 16:01 ET
|
ObsEva SA
ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market:...
ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023
March 15, 2023 07:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...